https://www.biopharmawatch.com/news/VNDA/nereus-sponsor-no-47-indycar-freedom-250-grand-prix BiopharmaWatch en 2026-08-22T19:16:00.000Z NEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C. https://www.biopharmawatch.com/news/ZURA/zura-bio-inducement-grants-nasdaq-listing-rule BiopharmaWatch en 2026-08-21T23:57:00.000Z Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-jury-finds-favor-patent-case BiopharmaWatch en 2026-08-21T20:35:00.000Z Jury Finds in Cytek’s Favor on Three of Four Asserted Claims; Company to Challenge Remaining Finding https://www.biopharmawatch.com/news/KAPA/kairos-pharma-reverse-stock-split-2026 BiopharmaWatch en 2026-08-21T20:30:00.000Z Kairos Pharma Announces 1-for-7 Reverse Stock Split https://www.biopharmawatch.com/news/ZVRA/zevra-therapeutics-inducement-grants-nasdaq-rule-5635c4 BiopharmaWatch en 2026-08-21T20:30:00.000Z Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/MOH/molina-healthcare-michigan-donation-hunger-housing BiopharmaWatch en 2026-08-21T20:00:00.000Z Molina Healthcare of Michigan Donates $85,000 to Support Two Organizations Addressing Hunger and Housing in Bay and Saginaw Counties https://www.biopharmawatch.com/news/MPLT/segal-trials-phase-2-zephyr-study BiopharmaWatch en 2026-08-21T15:33:00.000Z Segal Trials Reinforces Leadership in Acute Schizophrenia Research Following Participation in MapLight Therapeutics’ Phase 2 ZEPHYR Study https://www.biopharmawatch.com/news/HSDT/solana-company-governance-proposals-hsdt BiopharmaWatch en 2026-08-21T15:00:14.000Z Solana Company Announces Positions and Votes on first Solana Governance Proposals https://www.biopharmawatch.com/news/SRRK/scholar-rock-apitegromab-regulatory-update BiopharmaWatch en 2026-08-21T13:06:00.000Z Scholar Rock Provides Update on Global Apitegromab Regulatory Progress Across U.S., Europe, and Japan https://www.biopharmawatch.com/news/ALVO/alvotech-licensing-agreement-lotus-pharmaceutical BiopharmaWatch en 2026-08-21T13:00:00.000Z Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets https://www.biopharmawatch.com/news/DRMA/dermata-preorders-tome-treatment-launch BiopharmaWatch en 2026-08-21T12:30:00.000Z Dermata Announces Preorders Now Open for Tome Foundational Treatment Ahead of Commercial Launch https://www.biopharmawatch.com/news/RNXT/renovorx-regains-nasdaq-compliance-minimum-bid-price BiopharmaWatch en 2026-08-21T12:30:00.000Z RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement https://www.biopharmawatch.com/news/GOSS/gossamer-bio-private-placement-seralutinib-fda-approval BiopharmaWatch en 2026-08-21T12:00:00.000Z Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval https://www.biopharmawatch.com/news/AZTR/azitra-regains-compliance-nyse-american BiopharmaWatch en 2026-08-21T12:00:00.000Z Azitra, Inc. Regains Compliance with NYSE American Continued Listing Standards https://www.biopharmawatch.com/news/HOWL/werewolf-therapeutics-ambros-merger-agreement BiopharmaWatch en 2026-08-21T12:00:00.000Z Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 million Private Placement https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-phase-3-trial-etripamil-afib-rvr BiopharmaWatch en 2026-08-21T12:00:00.000Z Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR) https://www.biopharmawatch.com/news/SNYR/synergy-chc-corp-nasdaq-letter-receipt BiopharmaWatch en 2026-08-21T12:00:00.000Z Synergy CHC Corp. Announces Receipt of Nasdaq Letter https://www.biopharmawatch.com/news/ABBV/abbvie-new-data-wclc-2026-lung-cancer-pipeline BiopharmaWatch en 2026-08-21T11:45:00.000Z AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline https://www.biopharmawatch.com/news/CAPR/kaos-capital-calls-capricor-shareholders BiopharmaWatch en 2026-08-21T11:45:00.000Z Kaos Capital Calls on Capricor (NASDAQ: CAPR) Shareholders https://www.biopharmawatch.com/news/ABUS/arbutus-repurchases-common-shares-tender-offer BiopharmaWatch en 2026-08-21T11:30:00.000Z Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer https://www.biopharmawatch.com/news/JNJ/ec-approves-tecvayli-daratumumab-multiple-myeloma BiopharmaWatch en 2026-08-21T09:40:00.000Z European Commission approves Johnson & Johnson’s TECVAYLI®▼ (teclistamab) plus daratumumab for relapsed/refractory multiple myeloma, offering a potential new standard of care https://www.biopharmawatch.com/news/AVAH/aveanna-secondary-offering-pricing BiopharmaWatch en 2026-08-21T00:16:00.000Z Aveanna Announces Pricing of Secondary Offering of Common Stock